Seelos Therapeutics
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
300 Park Ave Fl 2, New York, New York, 1...Phone Number
(646) 293-2100Website
www.seelostherapeutics.comRevenue
$29.8 MillionStock Symbol
SEELIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.Explore more
Seelos Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Seelos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Seelos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Seelos Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Seelos Therapeutics
Click to see if Seelos Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Seelos Therapeutics recently announced quarterly report
Product Launch: Get notified when Seelos Therapeutics launches new products
Seelos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Seelos Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Seelos Therapeutics
Find 2 more new buyers
Compare Similar Companies to Seelos Therapeutics
Compare insights from companies similar to Seelos Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Seelos Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Seelos Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Seelos Therapeutics.
Seelos Therapeutics financials insights
Gather financial insights about Seelos Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$10M
2021
Stock Offering
$33.5M
Share Placement
$22M
Seelos Therapeutics Tech Stack
A closer look at the technologies used by Seelos Therapeutics
See more technologies
Most Recent Scoops
Pain Point
Pain Point, Bankruptcy
Project
Research & Development, Sales, Logistics / Supply Chain, Medical Research, Pharmaceuticals
Earnings
Earnings
Training, Financial Planning, Sales, Financial Systems, Sales Development, Financial Reporting, Financial Operations, Financial Strategy, Financial Transactions, Financing & Debt, Operations, Sales Enablement, Sales Operations, Sales Technology, Sales Training
Earnings
Financial Planning, Financial Systems, Financial Reporting, Financial Operations, Financial Strategy, Financial Transactions, Financing & Debt, Operations
Seelos Therapeutics News & Media
Seelos Announces Second Postponement of its Annual Meeting of Stockholders
NEW YORK, Oct. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of...Seelos Announces Postponement of its Annual Meeting of Stockholders
NEW YORK, Sept. 26, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of...Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
-Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare...Seelos Therapeutics Prices of $1.1 Million Registered Direct Offering and Concurrent Private Placement
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders... Read More The post Seelos Therapeutics Prices of $1.1 Million Registered Direct Offering and Concurrent Private Placement appeared first on citybiz.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Seelos Therapeutics
Sign Up For FreeTo access detailed company insights
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting... Read More
